Nasdaq

Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

– Acthar Gel Single-Dose Pre-filled SelfJect Injector is a self-controlled, pre-filled delivery device1 for appropriate patients with a range of chronic and acute inflammatory and autoimmune ...
Medscape

FDA Approves First Nalmefene Auto-Injector for Opioid Overdose

The US Food and Drug Administration (FDA) has approved the first nalmefene hydrochloride auto-injector (Zurnai; Purdue Pharma LP) for the treatment of known or suspected opioid overdose in people aged ...
Medscape

Nalmefene Auto-Injector: Concerns About the New Opioid Overdose Antidote Explained

The first nalmefene hydrochloride (HCl) auto-injector (Zurnai) brings a new tool to the fight against the opioid overdose epidemic but is not without controversy. As reported earlier this month, the ...
KTLA

Mallinckrodt Announces Publication of Real-World Insights on Patient Experience with Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

– Survey findings showed a majority of participants had a favorable experience injecting Acthar Gel via SelfJect, with a high level of satisfaction, confidence, convenience, and ease of use regarding ...